In summary, our data define additional CXCR4/CD5 subpopulations of divergent ages, phenotypes, and sensitivities to BTK inhibition, suggesting that CLL B-cell kinetics are more complex than the current model describes. The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.